COGNANO, Inc.

COGNANO, Inc. is a biotechnology company that integrates alpaca-derived antibody data with machine learning to accelerate drug discovery. The company operates its own alpaca colonies to generate large-scale datasets of heavy-chain antibodies (VHH). By applying computational science and proprietary algorithms, such as its Inverse Biomarker Exploring Technology (IBMET), COGNANO identifies critical target molecules and predicts antibody performance. This approach operates upstream of traditional drug development, enabling the discovery of therapeutic candidates for conditions with previously unknown targets, including triple-negative breast cancer and various infectious disease mutations.

By converting biological information into digital mathematical models, COGNANO aims to provide high-accuracy drug discovery seeds that address significant unmet medical needs. The company’s platform is designed to be more efficient than conventional antibody development processes by utilizing expansive, high-quality antigen-antibody pair data. Through collaborations with academic institutions and participation in initiatives like OpenFold, COGNANO contributes to AI-driven research in computational structural biology and the advancement of personalized medicine. Their work has been featured in peer-reviewed journals and presented at major AI conferences, supporting the development of novel anti-infective and therapeutic treatments.